Pretransplant Minimal Pleural and Peritoneal Effusion Is a Potential Poor Prognostic Indicator in Allogeneic Hematopoietic Stem Cell Transplantation

Overview

Journal Clin Transplant

Specialty General Surgery

Date 2025 Jan 6

PMID 39761366

Authors

Takashi Oyama

Akira Honda

Yasutaka Masuda

Ken Morita

Hiroaki Maki

Yosuke Masamoto

Mineo Kurokawa

Affiliations

Soon will be listed here.

Abstract

Background: Pleural effusion and ascites developing after allogeneic hematopoietic stem cell transplantation (allo-SCT) are generally associated with inferior overall survival (OS); however, the prognostic value of pretransplant effusion on transplant outcomes remained unclear.

Methods: We retrospectively evaluated minimal pleural effusion and ascites detected by computed tomography in 248 consecutive adult patients who underwent their first allo-SCT from January 2007 to December 2022.

Results: Forty-eight patients demonstrated minimal pleural effusion or ascites within 100 days before transplantation (Effusion group) and the other 200 had no effusion (No effusion group). Serum albumin level was significantly lower in the Effusion group than in the No effusion group (median 3.8 vs. 3.4 g/dL, p < 0.001). Performance status (PS) was significantly inferior and refined disease risk index tended to be higher in the Effusion group. The 2-year OS rate after transplantation was significantly worse in the Effusion group (57.1% vs. 36.7%, p < 0.001). The Effusion group had a significantly lower cumulative incidence of neutrophil and platelet engraftment and higher hepatic veno-occlusive disease. Moreover, a tendency toward higher cumulative incidence of relapse and non-relapse mortality was shown in the Effusion group. In multivariate analysis, the Effusion group had a significantly inferior OS with a hazard ratio of 1.848 (95% confidence interval 1.231-2.774), even after adjustment for disease risk, serum albumin level, PS, and Hematopoietic Cell Transplant-Comorbidity Index points.

Conclusion: Reflecting high disease activity and impaired general condition, pretransplant effusion can be a complementary indicator for poor prognosis in allo-SCT.

References

Berger J, Preusser M, Berghoff A, Bergen E . Malignant ascites: Current therapy options and treatment prospects. Cancer Treat Rev. 2024; 121:102646. DOI: 10.1016/j.ctrv.2023.102646. View

Modi D, Jang H, Kim S, Deol A, Ayash L, Bhutani D . Incidence, etiology, and outcome of pleural effusions in allogeneic hematopoietic stem cell transplantation. Am J Hematol. 2016; 91(9):E341-7. PMC: 6852667. DOI: 10.1002/ajh.24435. View

Mohty M, Malard F, Abecassis M, Aerts E, Alaskar A, Aljurf M . Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant. 2016; 51(7):906-12. PMC: 4935979. DOI: 10.1038/bmt.2016.130. View

Gerull S, Medinger M, Heim D, Passweg J, Stern M . Evaluation of the pretransplantation workup before allogeneic transplantation. Biol Blood Marrow Transplant. 2014; 20(11):1852-6. DOI: 10.1016/j.bbmt.2014.06.029. View

Su M, Cho S, Kung Y, Lin J, Lee W, Wang P . Update on the differential diagnosis of gynecologic organ-related diseases in women presenting with ascites. Taiwan J Obstet Gynecol. 2019; 58(5):587-591. DOI: 10.1016/j.tjog.2019.07.002. View

Lee S . Classification systems for chronic graft-versus-host disease. Blood. 2016; 129(1):30-37. PMC: 5216262. DOI: 10.1182/blood-2016-07-686642. View

Bittencourt H, Rocha V, Chevret S, Socie G, Esperou H, Devergie A . Association of CD34 cell dose with hematopoietic recovery, infections, and other outcomes after HLA-identical sibling bone marrow transplantation. Blood. 2002; 99(8):2726-33. DOI: 10.1182/blood.v99.8.2726. View

Gooley T, Chien J, Pergam S, Hingorani S, Sorror M, Boeckh M . Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med. 2010; 363(22):2091-101. PMC: 3017343. DOI: 10.1056/NEJMoa1004383. View

Kubo H, Imataki O, Fukumoto T, Kawanaka Y, Ishida T, Kubo Y . Potential factors for and the prognostic impact of ascites after allogeneic hematopoietic stem cell transplantation. Sci Rep. 2023; 13(1):13005. PMC: 10415345. DOI: 10.1038/s41598-023-39604-6. View

10.

Wiedermann C . Hypoalbuminemia as Surrogate and Culprit of Infections. Int J Mol Sci. 2021; 22(9). PMC: 8123513. DOI: 10.3390/ijms22094496. View

11.

Luther M, Henes F, Zabelina T, Massoud R, Janson D, Wolschke C . Spleen volume and length determined by computed tomography impact outcome after allogeneic stem cell transplantation for myelofibrosis. Bone Marrow Transplant. 2023; 58(7):755-761. DOI: 10.1038/s41409-023-01968-8. View

12.

Faiz S, Sahay S, Jimenez C . Pleural effusions in acute and chronic leukemia and myelodysplastic syndrome. Curr Opin Pulm Med. 2014; 20(4):340-6. DOI: 10.1097/MCP.0000000000000060. View

13.

Corbacioglu S, Jabbour E, Mohty M . Risk Factors for Development of and Progression of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome. Biol Blood Marrow Transplant. 2019; 25(7):1271-1280. DOI: 10.1016/j.bbmt.2019.02.018. View

14.

Armand P, Kim H, Logan B, Wang Z, Alyea E, Kalaycio M . Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. Blood. 2014; 123(23):3664-71. PMC: 4047501. DOI: 10.1182/blood-2014-01-552984. View

15.

Ryu J, Ryu H, Lee S, Memon A, Lee S, Nam H . Prognostic impact of minimal pleural effusion in non-small-cell lung cancer. J Clin Oncol. 2014; 32(9):960-7. DOI: 10.1200/JCO.2013.50.5453. View

16.

Chen Y, Huang H, Lin K, Medeiros L, Chen T, Chang K . Malignant effusions correlate with poorer prognosis in patients with diffuse large B-cell lymphoma. Am J Clin Pathol. 2015; 143(5):707-15. DOI: 10.1309/AJCP6LXA2LKFZAMC. View

17.

Gratwohl A, Stern M, Brand R, Apperley J, Baldomero H, de Witte T . Risk score for outcome after allogeneic hematopoietic stem cell transplantation: a retrospective analysis. Cancer. 2009; 115(20):4715-26. DOI: 10.1002/cncr.24531. View

18.

Oken M, Creech R, Tormey D, Horton J, Davis T, McFadden E . Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982; 5(6):649-55. View

19.

Pohlmann A, Bentgens E, Schulke C, Kuron D, Reicherts C, Marx J . Pretransplant spleen volume and outcome after hematopoietic stem cell transplantation (HSCT) in patients with acute myeloid leukemia (AML). Ann Hematol. 2023; 102(9):2543-2553. PMC: 10444671. DOI: 10.1007/s00277-023-05353-9. View

20.

Kasow K, Krueger J, Srivastava D, Li C, Barfield R, Leung W . Clinical utility of computed tomography screening of chest, abdomen, and sinuses before hematopoietic stem cell transplantation: the St. Jude experience. Biol Blood Marrow Transplant. 2009; 15(4):490-5. PMC: 2679960. DOI: 10.1016/j.bbmt.2008.11.033. View